Related references
Note: Only part of the references are listed.Vaxfectin® enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses
Martha Sedegah et al.
VACCINE (2010)
Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin
Larry R. Smith et al.
VACCINE (2010)
Vaxfectin (R), a cationic lipid-based adjuvant for protein-based influenza vaccines
Jukka Hartikka et al.
VACCINE (2009)
Vaxfectin (R)-adjuvanted seasonal influenza protein vaccine: Correlation of systemic and local immunological markers with formulation parameters
Mark Shlapobersky et al.
VACCINE (2009)
Analysis of biomarkers after intramuscular injection of Vaxfectin®-formulated hCMV gB plasmid DNA
Adrian Vilalta et al.
VACCINE (2009)
Use of vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus
Chien-Hsiung Pan et al.
CLINICAL AND VACCINE IMMUNOLOGY (2008)
Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus
Peggy A. Lalor et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Preparing for a possible pandemic: influenza A/H5N1 vaccine development
Wendy A. Keitel et al.
CURRENT OPINION IN PHARMACOLOGY (2007)
Vaxfectin™-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge
Gretchen S. Jimenez et al.
HUMAN VACCINES (2007)
Vaccination with polymerase chain reaction-generated linear expression cassettes protects mice against lethal influenza a challenge
Adrian Vilalta et al.
HUMAN GENE THERAPY (2007)
Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling
Amanda L. Gavin et al.
SCIENCE (2006)
Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, severe acute respiratory syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts
Rebecca L. Sheets et al.
TOXICOLOGICAL SCIENCES (2006)
Comparison of the immunological memory after DNA vaccination and protein vaccination against anthrax in sheep
UK Hahn et al.
VACCINE (2006)
Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M tuberculosis H37Rv
M Romano et al.
VACCINE (2006)
Vaxfectin™ enhances immunogenicity and protective efficacy of P-yoelii circumsporozoite DNA vaccines
M Sedegah et al.
VACCINE (2006)
I. Poloxamer- formulated plasmid DNA-based human cytomegalovirus vaccine: Evaluation of plasmid DNA biodistribution/persistence and integration
A Vilalta et al.
HUMAN GENE THERAPY (2005)
II.: Cationic lipid- formulated plasmid DNA-based Bacillus anthracis vaccine:: Evaluation of plasmid DNA persistence and integration potential
A Vilalta et al.
HUMAN GENE THERAPY (2005)
A cationic lipid-formulated plasmid DNA vaccine confers sustained anti body-mediated protection against aerosolized anthrax spores
G Hermanson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection
CP Locher et al.
VACCINE (2004)
Enhancing effect of vaxfectin on the ability of a Japanese encephalitis DNA vaccine to induce neutralizing antibody in mice
C Nukuzuma et al.
VIRAL IMMUNOLOGY (2003)
Salivary gland delivery of pDNA-cationic lipoplexes elicits systemic immune responses
V Sankar et al.
ORAL DISEASES (2002)
Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8+ T cells
AD Judge et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Improved tuberculosis DNA vaccines by formulation in cationic lipids
S D'Souza et al.
INFECTION AND IMMUNITY (2002)
Liposomal delivery of CTL epitopes to dendritic cells
G Chikh et al.
BIOSCIENCE REPORTS (2002)
Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization
L Reyes et al.
VACCINE (2001)
Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection
MM Soares et al.
JOURNAL OF IMMUNOLOGY (2001)
Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens
J Hartikka et al.
VACCINE (2001)
Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity
NP Restifo
CURRENT OPINION IN IMMUNOLOGY (2000)
Share Paper
